Market capitalization | $192.63m |
Enterprise Value | $-78.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.07 |
P/B ratio (TTM) P/B ratio | 2.13 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-93.66m |
Free Cash Flow (TTM) Free Cash Flow | $-73.36m |
Cash position | $295.28m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a Mind Medicine Inc - Ordinary Shares (Sub Voting) forecast:
9 Analysts have issued a Mind Medicine Inc - Ordinary Shares (Sub Voting) forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.32 -1.32 |
59%
59%
|
|
EBITDA | -92 -92 |
12%
12%
|
EBIT (Operating Income) EBIT | -94 -94 |
9%
9%
|
Net Profit | -98 -98 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.
Head office | Canada |
CEO | Robert Barrow |
Employees | 57 |
Founded | 2019 |
Website | www.mindmed.co |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.